Market Research > Industries > Healthcare

Market Research: Rx-to-OTC Switch: The Next Wave

Rx-to-OTC Switch: The Next Wave


Published December 2002

View PDF brochure

This report provides comprehensive analyses of 12 therapeutic classes and 36 different drugs to predict their likelihood for Rx-to-OTC switch in the United States over a five-year period (2002 to 2006). The study examines potential switches, forecasts sales, and analyzes the potential impact on the current OTC market. As a bonus, an overview of several recent switches is provided. (Y406A)

Order Online or Order Print

ORDER ONLINE
 
You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 16 500 (sixteen thousand five hundred US Dollars)]

INTRODUCTION [US$ 0]

RECENT RX-TO-OTC SWITCHES [US$ 2 250]

    LAMISIL AT [US$ 575]
    NICODERM CQ [US$ 575]
    NICORETTE [US$ 575]
    NIZORAL A-D [US$ 575]
    ROGAINE [US$ 575]

POTENTIAL RX-TO-OTC SWITCHES [US$ 10 500]

    ALLERGY RELIEF PRODUCTS [US$ 2 100]
    • Table 4A-1 OTC MARKET FOR ALLERGY MEDICATIONS, 2001
      ALLEGRA [US$ 325]
      • Table 4A-2 TRACEABLE MEDIA EXPENDITURES FOR ALLEGRA, 2001
      ATROVENT [US$ 325]
      CLARITIN [US$ 525]
      • Table 4A-3 TRACEABLE MEDIA EXPENDITURES FOR CLARITIN, 2001
      FLONASE [US$ 325]
      • Table 4A-4 TRACEABLE MEDIA EXPENDITURES FOR FLONASE, 2001
      NASONEX [US$ 325]
      • Table 4A-5 TRACEABLE MEDIA EXPENDITURES FOR NASONEX, 2001
      VANCENASE [US$ 325]
      ZYRTEC [US$ 525]
      • Table 4A-6 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      • Table 4A-7 TRACEABLE MEDIA EXPENDITURES FOR ZYRTEC, 2001
    ANALGESICS/ARTHRITIC PAIN RELIEVERS [US$ 2 100]
      BEXTRA [US$ 625]
      • Table 4B-1 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      CELEBREX [US$ 625]
      • Table 4B-2 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      • Table 4B-3 TRACEABLE MEDIA EXPENDITURES FOR CELEBREX, 2001
      IMITREX [US$ 625]
      • Table 4B-4 TRACEABLE MEDIA EXPENDITURES FOR IMITREX, 2001
      VIOXX [US$ 625]
      • Table 4B-5 TRACEABLE MEDIA EXPENDITURES FOR VIOXX, 2001
    ANTIFUNGALS [US$ 525]
    • Table 4C-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ATHLETE’S FOOT REMEDIES AND JOCK ITCH REMEDIES, 2001
      SPECTAZOLE [US$ 325]
      SPORANOX [US$ 325]
    ANTISEIZURE MEDICATIONS [US$ 525]
      NEURONTIN [US$ 425]
      • Table 4D-1 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
    ASTHMA TREATMENTS [US$ 2 100]
    • Table 4E-1 MANUFACTURERS’ SALES OF PRESCRIPTION ASTHMA MEDICATIONS, 2001
      ACCOLATE [US$ 425]
      BECONASE [US$ 425]
      PROVENTIL [US$ 425]
      SINGULAIR [US$ 425]
      • Table 4E-2 TRACEABLE MEDIA EXPENDITURES FOR SINGULAIR, 2001
      VANCERIL DS [US$ 425]
      VENTOLIN [US$ 425]
    CHOLESTEROL REDUCERS [US$ 2 100]
      LESCOL [US$ 525]
      LIPITOR [US$ 525]
      • Table 4F-1 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      • Table 4F-2 TRACEABLE MEDIA EXPENDITURES FOR LIPITOR, 2001
      MEVACOR [US$ 525]
      PRAVACHOL [US$ 525]
      • Table 4F-3 TRACEABLE MEDIA EXPENDITURES FOR PRAVACHOL, 2001
      ZOCOR [US$ 525]
      • Table 4F-4 TRACEABLE MEDIA EXPENDITURES FOR ZOCOR, 2001
    DIABETES TREATMENTS [US$ 525]
      GLUCOPHAGE [US$ 375]
      • Table 4G-1 TRACEABLE MEDIA EXPENDITURES FOR GLUCOPHAGE, 2001
    INCONTINENCE PRODUCTS [US$ 525]
      DETROL [US$ 325]
      • Table 4H-1 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      • Table 4H-2 TRACEABLE MEDIA EXPENDITURES FOR DETROL, 2001
      DITROPAN XL [US$ 325]
      • Table 4H-3 TRACEABLE MEDIA EXPENDITURES FOR DITROPAN, 2001
    ORAL CONTRACEPTIVES [US$ 525]
    OSTEOPOROSIS MEDICATIONS [US$ 1 050]
      ACTONEL [US$ 325]
      • Table 4J-1 TRACEABLE MEDIA EXPENDITURES FOR ACTONEL, 2001
      EVISTA [US$ 325]
      FOSAMAX [US$ 325]
      • Table 4J-2 TRACEABLE MEDIA EXPENDITUERES FOR FOSAMAX, 2001
      MIACALCIN [US$ 325]
    PROTON PUMP INHIBITORS [US$ 1 050]
      • Table 4K-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION ANTACIDS AND ANTIGAS PRODUCTS, 2001
      PRILOSEC [US$ 425]
      • Table 4K-2 TRACEABLE MEDIA EXPENDITURES FOR PRILOSEC, 2001
      PROTONIX [US$ 425]
      PREVACID [US$ 425]
      • Table 4K-3 TRACEABLE MEDIA EXPENDITURES FOR PREVACID, 2001
    SYSTEMIC VAGINAL YEAST INFECTION REMEDIES [US$ 525]
      DIFLUCAN [US$ 375]
      • Table 4L-1 SALES AND MARKET SHARE OF PFIZER’S AND PHARMACIA’S RX-TO-OTC SWITCH DRUGS, 2001
      • Table 4L-2 TRACEABLE MEDIA EXPENDITURES FOR DIFLUCAN, 2001

PHARMACISTS’ PERCEPTIONS OF POTENTIAL RX-TO-OTC SWITCHES
[US$ 5 250]

  • Table 5-1 CHARACTERISTICS OF THE SURVEY SAMPLE
  • Table 5-2 FORMER RX DRUGS DEEMED INAPPROPRIATE FOR OTC USE
  • Table 5-3 PHARMACISTS’ PERCEPTIONS OF RX-TO-OTC SWITCH CANDIDATES

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
  Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
  Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

 
Market Research
Overview
Industry Practices
Purchasing a Report
 
Report Catalogs
Full Reports Catalog >>
The People of Kline
Kline Team Bios
Upcoming Appearances
Our Philosophy
 
Client Success
View all Client Successes >>
 
Contact Us
Send a Consulting RFP
Purchase a Research Report
Request a Meeting
General Inquiries

Questions?

Call or Email Us